drugset / Trial / NCT02986139

Study to Assess the Injection Site Pain Associated With a New Etanercept Formulation in Adults With Rheumatoid Arthritis or Psoriatic Arthritis

NCT02986139

Phase 3 Completed 111 enrolled Amgen
RandomizedCrossoverQuadruple-blindSupportive care

Summary

The primary objective was to assess the injection site pain associated with the new formulation of etanercept compared with commercial etanercept in adults with rheumatoid arthritis (RA) or psoriatic arthritis (PsA) as measured by a visual analog scale (VAS).

Timeline

Start
2016-11-29
Primary completion
2017-09-08
Completion
2017-10-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Etanercept Protein / enzyme biologic 50 mg Subcutaneous

Indications